In addition, CD79B transcripts are significantly more abundant than CD79A (fourfold increase) in some lymphoid cancer cell lines, suggesting that CD79B could act as a putative tumor promoter in leukemic B-cells [62]. The gene discussed is CD79B; the disease is lymphoma.